US biotech major Biogen (Nasdaq: BIIB) has filled out its pipeline with Remedy Pharmaceuticals’ Cirara (intravenous glyburide), a neurology candidate under development to treat a certain kind of stroke.
It’s hoped that the drug, which has undergone Phase II testing, can be used to treat large hemispheric infarction (LHI), a severe form of stroke caused by brain swelling.
The US Food and Drug Administration has declared Ciara an orphan drug for this indication, and granted the treatment Fast Track designation.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze